12/06/2026
Setting a new standard in myopia control.
New clinical trial results from HOYA Vision Care and The Hong Kong Polytechnic University, presented at ARVO 2026, are demonstrating unprecedented outcomes in myopia management.
Key findings include:
• In children aged 7–12 years, MiYOSMART iQ delivered more than 100% average effectiveness in myopia control and achieved a 94% reduction in axial elongation.
• In children aged 4–12 years, myopia did not progress on average, with axial elongation remaining below or comparable to that of non-myopic eyes.
• The first-ever evidence of the efficacy of D.I.M.S. Technology-based myopia control in children as young as 4 years of age.
These results represent the highest efficacy in myopia control reported to date for eyeglass lenses based on D.I.M.S. Technology, marking an important milestone in advancing myopia management for children worldwide.
MiYOSMART iQ coming soon | https://www.hoyavision.com/au/vision-products/miyosmartvr25/